MedGenome-CGHC will now have cross functional team comprising of experienced medical geneticists, scientists and bioinformatics
MedGenome, India’s premier genomics based research and Diagnostics Company, today announced that as part of its growth plans, it has taken over the management and operations of the Centre For Genetic Health Care (CGHC) in Mumbai. It will henceforth be called MedGenome- Centre For Genetic Health Care (CGHC).
CGHC, a leading genetic centre, accredited by NABL and CAP and offering cytogenetic and FISH tests in pediatrics, prenatal, reproductive genetics and haematological oncology segments, has been at the forefront for providing Genetic counselling services. With this take over, it will be able to provide patients with a wide range of molecular tests across all the specialties like Reproductive, Neurology, Nephrology, Oncology, Cardiology, ENT, Endocrinology, Ophthalmology, rare diseases etc.
This will empower clinicians with validated and actionable clinical information to make effective treatment decisions for their patients. This will also bring a lot of synergy providing a unique opportunity for doctors and patient to leverage each other strengths.
MedGenome-CGHC will now have cross functional team comprising of experienced medical geneticists, scientists and bioinformatics etc, who can leverage knowledge and depth on patient scenarios with large amount of curated content for enhanced reporting. The centre will boast of a larger pool of genetic counselors with enhanced depth and experience across multiple therapy areas, latest techniques for testing such as Next generation sequencing (NGS) technology and access to internationally accredited laboratory with the College of American Pathologists (CAP) and National Accreditation Board for Testing and Calibration Laboratories (NABL).
Dr Hema Purandarey, Founder, CGHC said,“Genetics plays an important role in clinical practice right from prevention of genetic disorders by screening, diagnosis and management. About 60 per cent of pregnancy losses, 2-3 per cent of all neonate and 50 per centof childhood deafness, blindness, mental retardation and 1 to 10 per cent of all malignancies are directly due to genetic factors. We are glad to associate with MedGenome to offer the most advanced molecular genetic tests that help screen, diagnose and manage such genetic disorders.”
Dr VL Ramprasad, COO, MedGenome said,“We are keen on expanding our reach and serving more patients. With CGHC now being managed and operated by MedGenome, it will add many clinical tests especially in the prenatal segment to our growing test list and we would be able to offer more comprehensive solutions to the clinicians. Genetic testing today has eased the process of diagnosing the disease for the clinicians, thus reducing the trial and error methods. This has indeed augmented the quality of life and care. With increase in awareness and government intervention, genetic tests can be made accessible and affordable to maximize the benefit for all”.